封面
市场调查报告书
商品编码
1239510

坐骨神经痛治疗药物市场:按类型、药物类别和分销渠道分类:全球机会分析和行业预测,2021-2031 年

Sciatica Treatment Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日期: | 出版商: Allied Market Research | 英文 241 Pages | 商品交期: 2-3个工作天内

价格

预计2021年坐骨神经痛治疗药物市场规模将达到6.7802亿美元,2022-2031年復合年增长率为3.9%,2031年将达到9.9126亿美元。

坐骨神经痛是指主要影响坐骨神经的疼痛,坐骨神经是从下背部延伸到臀部和腿部的神经。 坐骨神经痛通常只影响下半身的一侧,但沿着神经路径的任何地方都可能发生疼痛,从下背部到臀部再到大腿和小腿后部。 此外,坐骨神经痛的常见症状包括坐着时腿部疼痛加剧、腿部灼痛或麻木,以及难以站立的疼痛。 此外,根据坐骨神经受影响的位置,您的脚和脚趾也可能会感到疼痛。 坐骨神经痛可以用多种药物和止痛药治疗。 药物包括消炎药、止痛药和抗惊厥药。

推动坐骨神经痛药物市场增长的主要因素是坐骨神经痛发病率的增加、开发新型坐骨神经痛治疗方法的研发活动激增,以及人们对坐骨神经痛及其治疗的关注。 在发展中国家和发达国家,坐骨神经痛的发病率都在增加,原因很多。 坐骨神经痛的主要原因是椎间盘突出、腰椎滑脱、椎间盘退变、椎管狭窄、腰椎滑脱。 根据约翰霍普金斯关节炎中心的数据,最近的人口估计表明美国强直性脊柱炎 (AS) 的患病率约为 0.2% 至 0.5%;对强直性脊柱炎 (AS) 的兴趣正在增加,估计患病率为 0.4 至 14每 100,000 人。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 顶级影响因子
    • 顶级投资基金
  • 波特的五力分析
    • 供应商议价能力强
    • 买家议价能力适中
    • 替代品的威胁是中等的
    • 新进入者的威胁中等
    • 对手实力适中
  • 市场动态
    • 司机
      • 坐骨神经痛发病率上升
      • 老年人口增加
      • 增加研发活动
    • 约束因素
      • 存在或不存在替代治疗
    • 机会
      • 新兴国家的增长机会
  • 分析 COVID-19 对市场的影响

第 4 章坐骨神经痛药物市场:按类型

  • 概览
    • 市场规模和预测
  • 急性坐骨神经痛
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 慢性坐骨神经痛
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析

第 5 章坐骨神经痛药物市场:按药物类别分类

  • 概览
    • 市场规模和预测
  • 非甾体抗炎药
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 类固醇
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 抗抑郁药
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析

第 6 章坐骨神经痛药物市场:按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 零售药店和专业药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场份额分析:国家/地区分析

第 7 章坐骨神经痛药物市场:按地区

  • 概览
    • 市场规模和预测:按地区
  • 北美
    • 主要趋势和机会
    • 市场规模/预测:按类型
    • 市场规模和预测:按药物类别
    • 市场规模和预测:按分销渠道
    • 市场规模/预测:按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
  • 欧洲
    • 主要趋势和机会
    • 市场规模/预测:按类型
    • 市场规模和预测:按药物类别
    • 市场规模和预测:按分销渠道
    • 市场规模/预测:按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
  • 亚太地区
    • 主要趋势和机会
    • 市场规模/预测:按类型
    • 市场规模和预测:按药物类别
    • 市场规模和预测:按分销渠道
    • 市场规模/预测:按国家/地区分类
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
  • 拉美
    • 主要趋势和机会
    • 市场规模/预测:按类型
    • 市场规模和预测:按药物类别
    • 市场规模和预测:按分销渠道
    • 市场规模/预测:按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道
      • LAMEA 的其余部分
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测:按类型
      • 市场规模和预测:按药物类别
      • 市场规模和预测:按分销渠道

第八章竞争格局

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 定位顶级公司,2021 年

第九章公司简介

  • Abbott Laboratories
  • Alkem Laboratories Ltd
  • Amneal Pharmaceuticals LLC
  • Johnson and Johnson
  • Sinfonia Biotherapeutics
  • Sorrento Therapeutics, Inc
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma
Product Code: A13379

The sciatica treatment market size was valued for $678.02 million in 2021 and is estimated to reach $991.26 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.  

Sciatica is referred to the pain that mainly affects sciatic nerves whereas sciatic nerves are the nerves that travel from the lower back through the hips and buttocks and down through each leg. Sciatica usually affects only one side of the lower body but the pain can occur in any part of the nerve pathway from the lower back to the buttock and the back of a thigh and calf. Furthermore, common symptoms of sciatica include pain in the leg which may worsen when sitting, burning or tingling down the leg, shooting pain that makes it difficult for the person to stand. Moreover, the pain may also occur in foot and toes, depending on the part of sciatic nerve affected. Sciatica can be treated using various medications or analgesic drugs. The medications include anti-inflammatory drugs, analgesic drugs, anti-convulsant and others.  

Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments. There is an increase in incidence of sciatica in the developing and developed countries which have many different causes. Sciatica is mainly caused due to herniated or slipped disk, degenerative disk, spinal stenosis, spondylolisthesis and others. According to the Johns Hopkins Arthritis Center, in the recent population estimates indicate that the prevalence of ankylosing spondylitis (AS) in the U.S. is approximately 0.2-0.5% and based on data from multiple countries, the age- and sex-adjusted incidence of ankylosing spondylitis (AS) is 0.4-14 per 100,000 people.  

In addition, in a year about 2% of people get a herniated disk. When a herniated disk happens to a vertebra in lower back, it can press on the sciatic nerve leading to sciatica. Thus, huge prevalence of such conditions leads to increase in incidences of sciatica. This, in turn, propels the growth of the sciatica treatment market. 

In addition, increase in R&D activities in pharmaceutical field is driving the growth of the market. Major players are focusing on developing new drugs and APIs having application in sciatica treatment that are potent and efficient. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to academic and private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug therapies for sciatica and other diseases, which further propels the growth of the market. 

Although, various key factors are driving the growth of the market, few factors such as lack of specific approved treatments for sciatica and presence of alternate treatment options hinder the growth of the market. Alternate treatment options including the physiotherapy, and bracing along with surgical treatment restrict the growth of the sciatica treatment market. However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. For instance, countries such as China and India with huge population base and high patient pool offer lucrative opportunities for the market growth. 

The sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers.  

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sciatica treatment market analysis from 2021 to 2031 to identify the prevailing sciatica treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the sciatica treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global sciatica treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Acute sciatica
  • Chronic sciatica
  • Others

By Drug class

  • Non-steroidal anti-inflammatory drugs
  • Steroids
  • Antidepressants
  • Others

By Distribution channel

  • Hospital pharmacies
  • Retail and specialty pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Abbott Laboratories
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma
  • Sorrento Therapeutics, Inc
  • Alkem Laboratories Ltd
  • Amneal Pharmaceuticals LLC
  • Johnson and Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Sinfonia Biotherapeutics
  • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidence of sciatica
      • 3.4.1.2. Increase in geriatric population
      • 3.4.1.3. Increase in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. Presence of alternate treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SCIATICA TREATMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Acute sciatica
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic sciatica
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: SCIATICA TREATMENT MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Non-steroidal anti-inflammatory drugs
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Steroids
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Antidepressants
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail and specialty pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: SCIATICA TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Alkem Laboratories Ltd
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Amneal Pharmaceuticals LLC
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Johnson and Johnson
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Sinfonia Biotherapeutics
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Sorrento Therapeutics, Inc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Zydus Lifesciences Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Aurobindo Pharma
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. SCIATICA TREATMENT MARKET FOR STEROIDS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. SCIATICA TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. U.S. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. CANADA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. MEXICO SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. EUROPE SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. GERMANY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. FRANCE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. UK SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. ITALY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. SPAIN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. CHINA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. AUSTRALIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. LAMEA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. BRAZIL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 89. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 90. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 91. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 92. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 93. ALKEM LABORATORIES LTD: KEY EXECUTIVES
  • TABLE 94. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 95. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
  • TABLE 96. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 97. ALKEM LABORATORIES LTD: KEY STRATERGIES
  • TABLE 98. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 99. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 100. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 101. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 102. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 103. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 104. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
  • TABLE 105. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 106. SINFONIA BIOTHERAPEUTICS: KEY EXECUTIVES
  • TABLE 107. SINFONIA BIOTHERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 108. SINFONIA BIOTHERAPEUTICS: PRODUCT SEGMENTS
  • TABLE 109. SINFONIA BIOTHERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 110. SINFONIA BIOTHERAPEUTICS: KEY STRATERGIES
  • TABLE 111. SORRENTO THERAPEUTICS, INC: KEY EXECUTIVES
  • TABLE 112. SORRENTO THERAPEUTICS, INC: COMPANY SNAPSHOT
  • TABLE 113. SORRENTO THERAPEUTICS, INC: PRODUCT SEGMENTS
  • TABLE 114. SORRENTO THERAPEUTICS, INC: PRODUCT PORTFOLIO
  • TABLE 115. SORRENTO THERAPEUTICS, INC: KEY STRATERGIES
  • TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 121. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 122. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 129. AUROBINDO PHARMA: KEY EXECUTIVES
  • TABLE 130. AUROBINDO PHARMA: COMPANY SNAPSHOT
  • TABLE 131. AUROBINDO PHARMA: PRODUCT SEGMENTS
  • TABLE 132. AUROBINDO PHARMA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. SCIATICA TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF SCIATICA TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN SCIATICA TREATMENT MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALSCIATICA TREATMENT MARKET
  • FIGURE 10. SCIATICA TREATMENT MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR STEROIDS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. SCIATICA TREATMENT MARKET BY REGION, 2021
  • FIGURE 24. U.S. SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: SCIATICA TREATMENT MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 51. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. ALKEM LABORATORIES LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. ALKEM LABORATORIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. JOHNSON AND JOHNSON: SALES REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. SORRENTO THERAPEUTICS, INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. SORRENTO THERAPEUTICS, INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. AUROBINDO PHARMA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 70. AUROBINDO PHARMA: REVENUE SHARE BY REGION, 2021 (%)